The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have a ER+/HER2- early breast cancer with no evidence of residual disease following surgery. The objective of this study is to see if study therapy with Camizestrant is better at preventing disease recurrence (disease that comes back) than standard endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen, the drugs that you and other patients with early ER+/HER2- breast cancer are currently receiving).
You could be on active treatment on this study for up to 7 years. Once you have completed the treatment portion of the study, you will enter the follow-up period for up to 6 years after your first dose of study treatment.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/study/NCT05952557
uvacancertrials@hscmail.mcc.virginia.edu
The (department, division name) seeks (insert as applies: adults/men/women/adolescents/children) ages (insert) with (insert condition) for a research study. The purpose of the study is (insert purpose of study - eg.to test the effectiveness of an investigational medicine; or to find out how stress effects blood pressure.)
(Optional)You may be eligible for this study if: (insert brief eligibility criteria 3 or 4 top criteria and in lay language. Do not copy eligibility criteria from the protocol)
Study involves (insert procedures-examples: taking an experimental medicine/placebo, blood draws, x rays, overnight stays,) (Insert x number of visits every x (weeks, months,) each visit lasting x amount of time or give range).
Insert one of the following:
Study-related (insert exams, tests and experimental medication) provided at no cost.
or
Participant’s insurance company will be billed for medication, test,s and procedures
66.67 per completed visit